We are live on ! Find out more
LVTX

LAVA Therapeutics
LVTX

Delisted

LVTX was delisted on the 20th of November, 2025.

Back to rankings

24 hedge funds and large institutions have $139M invested in LAVA Therapeutics in 2021 Q1 according to their latest regulatory filings, with 24 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

36.38% more ownership

Funds ownership: 0% → 36.38% (+36%)

Holders
24
Holders Change
+24
Holders Change %
–
% of All Funds
0.42%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NHAS
Novo Holdings A/S
Denmark
+$45.7M
2
RG
Redmile Group
California
+$38.8M
3
NIP
Nicholas Investment Partners
California
+$11.2M
4
NCM
Nantahala Capital Management
Connecticut
+$5.24M
5
MIM
Monashee Investment Management
Massachusetts
+$3.64M

Top Sellers

No sellers this quarter

LVTX Hedge Fund Activity: Q1 2021 in Review

24 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in LAVA Therapeutics (LVTX) for Q1 2021, worth a combined $139M.

Buyers outnumbered sellers: 24 funds opened new LVTX positions and 0 closed out — a net gain of 24 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $45.7M.

  • 24 institutional investors held LAVA Therapeutics (LVTX) as of Q1 2021, up from 0 in Q4 2020.
  • Funds reported $139M of LAVA Therapeutics stock for Q1 2021.
  • 24 funds opened new LAVA Therapeutics positions in Q1 2021 and 0 closed out, a net change of +24 holders.
  • The largest LAVA Therapeutics buyer in Q1 2021 was Novo Holdings A/S, an estimated $45.7M added.

Based on aggregated 13F filings for Q1 2021.